Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | $2.91B |
| Gross Profit (TTM) | $1.60B |
| EBITDA | $875.83M |
| Operating Margin | 17.10% |
| Return on Equity | 3.21% |
| Return on Assets | 2.37% |
| Revenue/Share (TTM) | $25.77 |
| Book Value | $64.78 |
| Price-to-Book | 2.02 |
| Price-to-Sales (TTM) | 4.99 |
| EV/Revenue | 5.8 |
| EV/EBITDA | 21.88 |
| Quarterly Earnings Growth (YoY) | 1.20% |
| Quarterly Revenue Growth (YoY) | 1.30% |
| Shares Outstanding | $111.59M |
| Float | $102.48M |
| % Insiders | 0.27% |
| % Institutions | 103.80% |
Volatility is currently contracting
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird's 2026 Global Healthcare Conference Tuesday, September.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an.
Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.
Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript
Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RVTY and any ticker you trade — then tracks every position and per-strategy win rate.
